Prior to vaccine availability, RSV was a significant cause of illness and hospitalization in older adults in the U.S., ...

Dormitzer also took the lead on Pfizer's respiratory syncytial virus (RSV) vaccine candidates ... now started testing, while GSK has also focused on providing its adjuvant technology to other ...

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Despite 50 years of research, there are currently no RSV vaccines ... pregnant women. GlaxoSmithKline is evaluating a prefusion F protein vaccine in adults with an undisclosed adjuvant(s).

Respiratory syncytial virus (RSV) is a leading ... and pregnant women. GlaxoSmithKline is evaluating a prefusion F protein vaccine in adults with an undisclosed adjuvant(s). MedImmune is assessing ...

“Faisal has a proven track record in integrating cutting-edge science with practical, evidence-base PHILADELPHIA, October 24, 2024--New data for AREXVY, GSK’s RSV vaccine, show potential to ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Local health boards invited adults aged 75–79, including those turning 75 before July 2025, to come forward for their free RSV vaccine ahead of the winter. By the end of November 2024 ...

The Government of Canada has secured an initial supply of 500,000 doses of GSK's bird flu vaccine to protect individuals most ...

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...